Stockscreener 앱 받기
3.94
12.57%
0.44
시간 외 거래:
4.13
0.19
+4.82%
Briacell Therapeutics Corp 주식(BCTX)의 최신 뉴스
Virtu Financial LLC Makes New $27,000 Investment in BriaCell Therapeutics Corp. (NASDAQ:BCTX) - Defense World
BriaCell Therapeutics (OTCMKTS:BCTXF) Shares Up 4% – Here’s What Happened - Defense World
BriaCell Therapeutics (NASDAQ:BCTX) Trading 4% Higher – Time to Buy? - Defense World
(BCT) Technical Patterns and Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update - Defense World
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - GlobeNewswire
BriaCell to Showcase Cancer Immunotherapy Advances at AACR 2025 - TipRanks
New Clinical Data: BriaCell's Registration Trial Results for Advanced Breast Cancer Treatment - Stock Titan
Where Will Rigetti Computing Stock Be in 1 Year? - The Globe and Mail
Dan Ives Is Pounding the Table on Microsoft Stock. Should You Buy the Dip? - The Globe and Mail
Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? - The Globe and Mail
(BCT) Stock Evaluation Report (BCT:CA) - Stock Traders Daily
(BCT) Market Dynamics and Trading Signals (BCT:CA) - news.stocktradersdaily.com
What To Expect From Carnival’s (CCL) Q1 Earnings - The Globe and Mail
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review By Investing.com - Investing.com South Africa
Stocks In Play: BriaCell Therapeutics Corp By Baystreet.ca - Investing.com Canada
(BCT) Technical Analysis and Trading Signals (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp - Baystreet.ca
Stocks in play: BriaCell Therapeutics Corp - The Globe and Mail
BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer - MarketScreener
BriaCell’s Phase 3 Metastatic Breast Cancer Study Receives Positive DSMB Review - TipRanks
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review - Investing.com
Second Data Safety Monitoring Board Issues Positive - GlobeNewswire
Major Milestone: BriaCell's Breast Cancer Immunotherapy Passes Critical Safety Review in Phase 3 Trial - Stock Titan
3 Reasons DRS is Risky and 1 Stock to Buy Instead - The Globe and Mail
Briacell Therapeutics Corp reports results for the quarter ended January 31Earnings Summary - TradingView
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Growth in Short Interest - Defense World
Briacell Therapeutics Corp expected to post a loss of $1.12 a shareEarnings Preview - TradingView
3 Industrials Stocks Walking a Fine Line - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Trading 0.3% Higher – Here’s Why - Defense World
BriaCell Therapeutics Reports Continued Financial Challenges - TipRanks
BriaCell subsidiary reports interim financial results By Investing.com - Investing.com Australia
BriaCell Therapeutics Corp. SEC 10-Q Report - TradingView
BriaCell subsidiary reports interim financial results - Investing.com India
BriaCell Therapeutics (BCTX) Projected to Post Quarterly Earnings on Monday - Defense World
BCTX stock touches 52-week low at $3.31 amid sharp annual decline By Investing.com - Investing.com South Africa
BCTX stock touches 52-week low at $3.31 amid sharp annual decline - Investing.com
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World
BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World
Dye & Durham Limited - Baystreet.ca
(BCT) Equity Trading Insights (BCT:CA) - Stock Traders Daily
(BCT) Market Performance Analysis (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp (NASDAQ: BCTX) – An Analysis Is What You Need - Stocks Register
(BCT) Investment Analysis (BCT:CA) - Stock Traders Daily
(BCT) Trading Advice (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - MarketBeat
BriaCell regains Nasdaq compliance with bid price By Investing.com - Investing.com Australia
BriaCell regains Nasdaq compliance with bid price - MSN
10.70%
자본화:
|
볼륨(24시간):